Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma

Oncology Reports

Volumn 13, Issue 2, 2005, Pages 335-340

  Beetz, Christian ^a   Brodoehl, Stefan ^a   Patt, Stephan ^a   Kalff, Rolf ^a   Deufel, Thomas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Chromosome 9; Deleted in bladder cancer chromosomal region 1; Gene expression; Glioma; Loss of heterozygosity; Tumour suppressor gene

Indexed keywords

DBC1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CHROMOSOME 9; GENE DELETION; GENE EXPRESSION; GENETICS; HUMAN; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 9; GENE DELETION; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 16244393417     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cairns P, Shaw ME and Knowles MA: Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8: 1083-1085, 1993.
2. Ruppert JM, Tokino K and Sidransky D: Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53: 5093-5095, 1993. (Pubitemid 23333370)
3. Keen AJ and Knowles MA: Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9: 2083-2088, 1994. (Pubitemid 24194178)
4. Williamson MP, Elder PA, Shaw ME, Devlin J and Knowles MA: p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577, 1995.
5. Akao T, Kakehi Y, Itoh N, Ozdemir E, Shimizu T, Tachibana A, Sasaki MS and Yoshida O: A high prevalence of functional inactivation by methylation modification of p16INK4A/CDKN2/MTS1 gene in primary urothelial cancers. Jpn J Cancer Res 88: 1078-1086, 1997. (Pubitemid 28021479)
6. Grim J, D'Amico A, Frizelle S, Zhou J, Kratzke RA and Curiel DT: Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin Cancer Res 3: 2415-2423, 1997. (Pubitemid 28133163)
7. Habuchi T, Yoshida O and Knowles MA: A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Hum Mol Genet 6: 913-919, 1997. (Pubitemid 27239077)
8. Habuchi T, Luscombe M, Elder PA and Knowles MA: Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48: 277-288, 1998. (Pubitemid 28180727)
9. Kimura F. Florl AR, Seifert HH, Louhelainen J, Maas S, Knowles MA and Schulz WA: Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 85: 1887-1893, 2001. (Pubitemid 34775326)
10. Wada T, Berggren P, Steineck G, Adolfsson J, Wijkstrom H, Norming U, Hansson J, Hemminki K and Larsson P: Bladder neoplasms - regions at chromosome 9 with putative tumour suppressor genes. Scand J Urol Nephrol 37: 106-111, 2003. (Pubitemid 36535227)
11. Nishiyama H, Takahashi T, Kakehi Y, Habuchi T and Knowles MA: Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer 26: 171-175, 1999. (Pubitemid 29416443)
12. Stadler WM, Steinberg G, Yang X, Hagos F, Turner C and Olopade OI: Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 7: 1676-1682, 2001. (Pubitemid 32708635)
13. Fujiwara H, Emi M, Nagai H, Ohgaki K, Imoto I, Akimoto M, Ogawa O and Habuchi T: Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell line. J Hum Genet 46: 372-377, 2001. (Pubitemid 32634512)
14. Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, Akao T, Sato K, Ogawa O, Knowles MA and Kato T: Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urolhelium and an early and frequent alteration in bladder cancer. Oncogene 20: 531-537, 2001. (Pubitemid 32158233)
15. Nishiyama H, Gill JH, Pitt E, Kennedy W and Knowles MA: Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 20: 2956-2964, 2001. (Pubitemid 33027763)
16. Wright KO, Messing EM and Reeder JE: DBCCR1 mediates death in cultured bladder tumor cells. Oncogene 23: 82-90, 2004. (Pubitemid 38142242)
17. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF and Zhu JD: Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 13: 319-333, 2003. (Pubitemid 43231848)
18. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T and Kassem M: Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23: 5095-5098, 2004. (Pubitemid 38938744)
19. Kleihues P and Cavanee WK: Pathology and Genetics - Tumours of the central nervous system. IARC Press, Lyon, 2000.
20. Beetz C, Hartmann A, Kiehntopf M, Wölfl S, Kalff R, Deufel T and Patt S: Rapid generation of detailed loss of heterozygosity profiles for routine diagnosis of gliomas. Clin Chem Lab Med 42: 595-601, 2004. (Pubitemid 38979135)
21. Sheffield VC, Weber JL, Buetow KH, Murray JC, Even DA, Wiles K, Gastier JM, Pulido JC, Yandava C, Sunden SL, et al: A collection of tri- and telranucleotide repeat markers used to generate high quality, high resolution human genome-wide linkage maps. Hum Mol Genet 4: 1837-1844, 1995.
22. Wright KO, Messing EM and Reeder JE: Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. J Urol 168: 2645-2649, 2002. (Pubitemid 35402709)
23. Knowles MA: The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84: 412-427, 1999. (Pubitemid 29419407)
24. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M. Varis A, Wasenius VM, Wolf M and Zhu Y: DNA copy number losses in human neoplasms. Am J Pathol 155:683-694, 1999. (Pubitemid 29426813)
25. Baudis M and Cleary ML: Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 17: 1228-1229, 2001. (Pubitemid 33735351)
26. Maruno M, Yoshimine T, Muhammad AK, Tokiyoshi K and Hayakawa T: Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications. J Neurooncol 30: 19-24, 1996. (Pubitemid 26265766)
27. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH and McLendon RE: Molecular markers of prognosis in astrocytic tumors. Cancer 94: 2688-2697, 2002. (Pubitemid 34478085)
28. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971.
29. Balmain A, Gray J and Ponder B: The genetics and genomics of cancer. Nat Genet 33 (Suppl): 238-244, 2003. (Pubitemid 36278834)
30. Uhlmann K, Rohde K, Zeller C. Szymas J, Vogel S, Marczinek K, Thiel G, Nurnberg P and Laird PW: Distinct methylation profiles of glioma subtypes. Int J Cancer 106: 52-59, 2003. (Pubitemid 36750387)
31. Dallol A, Krex D, Hesson L, Eng C, Malier ER and Latif F: Frequent epigenetic inactivation of the SLIT2 gene in gliomas Oncogene 22: 4611 -4616, 2003. Kunst